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Biventricular assistance with the Jarvik FlowMaker: A case report
O. H. Frazier, MD, Timothy J. Myers, BS, and Igor Gregoric, MD, Houston, Tex
After implantation of a left ventricular assist device(LVAD), right ventricular dysfunction and elevatedperipheral vascular resistance may result in right ven-tricular failure and increased mortality. Right ventric-
ular support may become necessary, as in the following case in
which two Jarvik FlowMakers (Jarvik Heart, Inc, New York, NY)
provided biventricular assistance.
Clinical Summary
A 21-year-old man with end-stage idiopathic cardiomyopathy was
referred to our hospital and approved for heart transplantation. He
had a left ventricular ejection fraction lower than 20% with mitral
and tricuspid regurgitation. Despite maximal medical therapy and
balloon counterpulsation, LVAD support became necessary as a
lifesaving measure. A Jarvik FlowMaker was implanted in the left
ventricle through a midline sternotomy with outflow graft anasto-
mosis to the ascending aorta.1 On postoperative day 1, the cardiac
index increased by 60%, from 1.5 to 2.3 L/(min · m2). The patient
was extubated on day 3. Two days later, he had ventricular
tachycardia that responded to drug therapy and cardioversion.
Sepsis supervened, hepatic function deteriorated, and the white
blood cell count rose to 28.2 103 cells/L. On postoperative day
12, respiratory failure and bradycardia necessitated resuscitation
and reintubation. Right ventricular function worsened, and tricus-
pid regurgitation became severe. A right atrial pressure greater
than 20 mm Hg was required for adequate cardiac output. Hepatic
function further deteriorated, and right ventricular support was
clinically necessary. Because of the FlowMaker’s unique suitabil-
ity for intracardiac placement and its ease of implantation without
cardiopulmonary bypass, this device was implanted for right ven-
tricular support on postoperative day 15. A purse-string suture was
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Figure 1. A, Configuration of biventricular FlowMaker system (right lateral viewpoint). B, Postoperative chest
radiograph.
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placed on the upper lateral wall of the right atrium, and the pump
was inserted into the atrium (Figure 1). The cardiac index in-
creased to greater than 3.0 L/(min · m2), maintaining the central
venous pressure at 5 to 10 cm H2O. Unfortunately, because of
progressive sepsis and hepatic failure, the patient died after 27
days of LVAD support and 12 days of biventricular support. Both
pumps had a typical appearance at removal, and autopsy findings
were unremarkable.
Discussion
Although implantable pulsatile LVADs can save patients with
end-stage heart failure, these devices may impair right ventricular
function. This problem is usually overcome by relieving the high
left-sided pressures typical of severe heart failure. However, when
left ventricular filling remains inadequate despite pharmacotherapy
to enhance right ventricular function and lower pulmonary vascu-
lar resistance, a right ventricular assist device may be required.
Unfortunately, implantation is frequently delayed until end-organ
failure is irreversible, and the mortality remains high even when a
physiologic cardiac output is achieved.
Continuous-flow LVADs unload the ventricle throughout the
cardiac cycle. Pulsatility is generated by native ventricular con-
traction, which is generally improved by the unloading achieved
by the FlowMaker. However, if impaired right-sided function
and/or increased pulmonary vascular resistance occurs (as in this
patient), impaired left ventricular filling will result. This will cause
ventricular and atrial septal shifting (Figure 2). Attempts to en-
hance left-sided output by increasing device speed (in hopes of
increasing flow) only worsen the situation.2
Implantable LVADs are not designed for right-sided support.
However, the FlowMaker’s intracardiac placement makes it
uniquely suitable as an implantable support device for either the
pulmonary or systemic circulation. Device placement was
achieved in the right atrium without cardiopulmonary bypass. By
directing the inlet toward the inferior vena caval–right atrial junc-
tion and keeping right atrial pressures at 5 to 10 cm H2O, we were
able to achieve reliable right ventricular unloading and deliver
satisfactory blood flow to the left-sided pump.
This therapy failed to save our critically ill patient. More timely
implantation of a FlowMaker right ventricular assist device, along
with a pulsatile or nonpulsatile LVAD, may be lifesaving in future
cases. A FlowMaker right ventricular assist device alone may also
be appropriate for long-term or destination therapy for isolated
right ventricular failure or for congenital heart disease involving
compromised or absent right ventricular function.
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Figure 2. Echocardiograms showing atrial septal shift with left-sided support alone (A) and normalization of
septum after placement of right-sided pump (B). S, Septum; LA, left atrium; RA, right atrium; L, left-sided pump; R,
right-sided pump.
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